Avidity Biosciences, Inc.
RNA
$49.77
-$1.00-1.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 88.12% | -55.60% | 35.57% | -17.10% | -11.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 88.12% | -55.60% | 35.57% | -17.10% | -11.70% |
| Cost of Revenue | 116.02% | 48.87% | 81.05% | 61.79% | 49.84% |
| Gross Profit | -116.94% | -54.71% | -83.02% | -66.74% | -53.37% |
| SG&A Expenses | 77.82% | 141.76% | 75.80% | 69.52% | 68.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.67% | 64.86% | 79.82% | 63.52% | 54.09% |
| Operating Income | -107.13% | -70.39% | -81.28% | -67.39% | -56.98% |
| Income Before Tax | -122.22% | -68.14% | -69.18% | -53.55% | -50.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -122.22% | -68.14% | -69.18% | -53.55% | -50.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.22% | -68.14% | -69.18% | -53.55% | -50.54% |
| EBIT | -107.13% | -70.39% | -81.28% | -67.39% | -56.98% |
| EBITDA | -107.87% | -70.79% | -81.85% | -67.80% | -57.26% |
| EPS Basic | -83.30% | -13.48% | -0.13% | 7.77% | -0.52% |
| Normalized Basic EPS | -83.30% | -13.48% | -0.14% | 7.77% | -0.51% |
| EPS Diluted | -83.30% | -13.92% | -0.13% | 7.77% | -0.52% |
| Normalized Diluted EPS | -83.30% | -13.48% | -0.14% | 7.77% | -0.51% |
| Average Basic Shares Outstanding | 21.22% | 48.18% | 68.96% | 66.50% | 49.78% |
| Average Diluted Shares Outstanding | 21.22% | 48.18% | 68.96% | 66.50% | 49.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |